Claims for Patent: 10,363,307

Summary for Patent: 10,363,307

Title:	Methods of treating psoriatic arthritis using IL-17 antagonists
Abstract:	The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
Inventor(s):	Mpofu; Shephard (Oberwil, CH), Richards; Hanno (Therwil, CH), Thangavelu; Karthinathan (Geneva, CH), Machacek; Matthias (Allschwil, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	15/654,854
Patent Claims:	1. A method of treating Psoriatic Arthritis (PsA), comprising: a) subcutaneously administering to a patient having PsA five doses of about 150 mg-about 300 mg of an IL-17 antibody, each of the five doses being delivered weekly; and b) thereafter, subcutaneously administering to the patient a dose of about 150 mg-about 300 mg of the IL-17 antibody every month, wherein the IL-17 antibody comprises: i) an immunoglobulin V.sub.H domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V.sub.L domain comprising the amino acid sequence set forth as SEQ ID NO:10; ii) an immunoglobulin V.sub.H domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:1-3, respectively, and an immunoglobulin V.sub.L domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:4-6, respectively; or iii) an immunoglobulin V.sub.H domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:11-13, respectively, and an immunoglobulin V.sub.L domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:4-6, respectively. 2. The method according to claim 1, wherein the IL-17 antibody is secukinumab. 3. The method according to claim 1, wherein, prior to treatment with the IL-17 antibody, the patient had an inadequate response to, had failure to, or was intolerant to treatment with a TNF alpha antagonist. 4. The method according to claim 1, wherein the patient has co-existing moderate to severe plaque psoriasis. 5. The method according to claim 1, further comprising administering a DMARD to the patient. 6. The method according to claim 5, wherein the DMARD is methotrexate. 7. A method of treating PsA in a patient, comprising administering about 150 mg--about 300 mg of secukinumab by subcutaneous injection to the patient at weeks 0, 1, 2, 3 and 4, followed by about 150 mg--about 300 mg of secukinumab every 4 weeks. 8. The method according to claim 7, wherein the patient has active PsA. 9. The method according to claim 7, wherein, prior to treatment with secukinumab, the patient had an inadequate response to, had failure to, or was intolerant to treatment with a TNF alpha antagonist. 10. The method according to claim 7, wherein the patient has co-existing moderate to severe plaque psoriasis. 11. The method according to claim 7, further comprising administering a DMARD to the patient. 12. The method according to claim 11, wherein the DMARD is methotrexate. 13. The method according to claim 7, comprising administering about 300 mg of secukinumab by subcutaneous injection to the patient at weeks 0, 1, 2, 3 and 4, followed by 300 mg of secukinumab every 4 weeks. 14. The method according to claim 13, wherein the patient has active PsA. 15. The method according to claim 13, wherein, prior to treatment with secukinumab, the patient responded inadequately to treatment with at least one DMARD. 16. The method according to claim 13, wherein, prior to treatment with secukinumab, the patient had an inadequate response to, had failure to, or was intolerant to treatment with a TNF alpha antagonist. 17. The method according to claim 13, wherein the patient has co-existing moderate to severe plaque psoriasis. 18. The method according to claim 13, further comprising administering a DMARD to the patient. 19. The method according to claim 18, wherein the DMARD is methotrexate. 20. The method according to claim 7, comprising administering about 150 mg of secukinumab by subcutaneous injection to the patient at weeks 0, 1, 2, 3 and 4, followed by 150 mg of secukinumab every 4 weeks. 21. The method according to claim 20, wherein the patient has active PsA. 22. The method according to claim 20, wherein, prior to treatment with secukinumab, the patient responded inadequately to treatment with at least one DMARD. 23. The method according to claim 20, wherein, prior to treatment with secukinumab, the patient had an inadequate response to, had failure to, or was intolerant to treatment with a TNF alpha antagonist. 24. The method according to claim 20, wherein the patient has co-existing moderate to severe plaque psoriasis. 25. The method according to claim 20, further comprising administering a DMARD to the patient. 26. The method according to claim 25, wherein the DMARD is methotrexate.

Details for Patent 10,363,307

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	Injection	125504	01/21/2015		2030-11-05
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	For Injection	125504	01/21/2015		2030-11-05
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	Injection	125504	05/28/2021		2030-11-05